Abstract: Ligand reagents are disclosed which consist essentially of recombinant hyperglycosylated cytokines, expressed in yeast, which are purified and conjugated to various functional moieties, for example, biotin groups, via oligosaccharide residues.

Abstract: The present invention relates to a novel .alpha.-glucosidase inhibitor, pradimicin Q, having the following formula ##STR1## and its pharmaceutically acceptable base salts.

Abstract: The present invention provides a dye other than red and purple which is obtained from cultured cells of Euphorbia milli. The present invention also provides cultured cells containing quercetin glucuronide in a large amount, derived from tissues or cells of Euphorbia milli.

Abstract: The present invention provides a process for the detection of analytes in body fluids containing free biotin by immunoassay with the use of biotin conjugates for the labelling, immobilization or complexing of immunological reagents, wherein the biotin present in free form is removed from the immunological reaction by incubating the sample solution with polymer particles consisting of a core and a covering which, as core, contain a polymer which has a plurality of binding sites for biotin and, as covering, at least one layer of protein, peptide, carbohydrate or co-polymer of carbohydrate and amino acids, the layer thickness of the covering being so adjusted that the coating is permeable for the free biotin but not for the biotin conjugate.

Abstract: Rapid assays for analytes of interest in a fluid sample utilize a first conjugate of a labelled reactant that specifically binds to the analyte, and a second conjugate that binds to the analyte coupled to a polymer that has an affinity for a selected solid phase. The reaction components are incubated briefly, then contacted with the selected solid phase and the labelled components determined. Optional wash steps provide for enhanced sensitivity and specificity. When the analyte of interest is an antibody to HIV, the first reactant may be a synthetic, recombinant or native HIV antigen, and the second reactant may be protein A or an anti-immunoglobulin.

Abstract: The concentration of glycated hemoglobin, HbA.sub.1c, in hemoglobin from diabetic patients is regarded as a useful means of assessing the adequacy of diabetes control. This invention comprises a monoclonal antibody which, due to its specific binding of HbA.sub.1c, can be used for the determination of HbA.sub.1c in the absence of prior denaturation, in blood samples by such analytical methods as radioimmuno assay or enzyme-linked immunosorbent assay. The invention also comprises hybridoma cell lines which produce monoclonal antibodies of the invention.

Abstract: New fermentation products A83543L, A83543M, and A83543N, N-demethyl derivatives thereof, and salts thereof, are useful for the control of insects. A83543PsaL1 is useful for the preparation of A83543 components. Methods for making A83543J, A83543L, A83543M, and A83543N by culture of Saccharopolyspora spinosa NRRL 18719 or NRRL 18720 are provided. Insecticidal and ectoparasiticidal compositions containing A83543L, A83543M, A83543N, and N-demethyl derivatives thereof are also provided.

Abstract: Biologically active reactive are prepared from particles of copolymers having polyoxyalkylene side chains, each of which side chains has a molecular weight of at least about 88. The reagents are prepared by covalently attaching biologically active substances, for example antibodies, to the particles, directly or indirectly through reactive groups on the particle surface. These reagents are used to advantage in analytical elements and methods for the detection of specific binding ligands (such as immunological species) and immunoassays, and in purification methods as affinity chromatography reagents. Adsorption of undesirable proteins on the particles of the reagents was considerably reduced because of the specific composition of the particles.

Abstract: The present invention concerns a method to catalyze reporter deposition to improve detection or quantitation of an analyte in a sample by amplifying the detector signal which comprises reacting an analyte dependent enzyme activation system with a conjugate consisting of a detectably labeled substrate specific for the enzyme system, said conjugate reacts with the analyte dependent enzyme activation system to form an activated conjugate which deposits substantially wherever receptor for the activated conjugate is immobilized, said receptor not being reactive with the analyte dependent enzyme activation system. In another embodiment the invention concerns an assay for detecting or quantitating the presence or absence of an analyte in a sample using catalyzed reporter deposition to amplify the reporter signal.

Abstract: The present invention relates to a fermentation process for producing BMY-28960 and desxylosyl BMY-28960, and to a novel BMY-28960-producing organism belonging to the genus Actinomadura and designated as strain AB 1236 (ATCC 55208).

Abstract: An immunoassay procedure is provided which exhibits increased specificity over current procedures. The procedure allows the differentiation of animals infected with Brucella abortus from animals vaccinated with Brucella abortus Strain 19. The invention employs unique monospecific monoclonal antibodies having particular affinity, specificity and binding characteristics directed to a B. abortus lipopolysaccharide antigen. The invention also concerns continuous hybrid cell lines for producing the unique monoclonal antibodies.

Abstract: A rapid, competitive enzyme linked immunosorbent assay (cELISA) for the determination of Bluetongue virus antibodies in serum is described. This method utilizes either a biotinylated monoclonal antibody to Bluetongue virus and streptavadin-enzyme in conjunction with synthetic substrate, or an enzyme-conjugated monoclonal to detect antibodies specific for Bluetongue virus.

Abstract: Avermectin aglycones are glycosylated by fermentation in a medium of a non-producing mutant of Streptomyces avermitilis MA-6078. The glycosylation produces the monosaccharide and disaccharide derivatives while leaving the remainder of the molecule intact. The microorganism glycosylates with the .alpha.-L-oleandrose moiety.

Abstract: It was possible to increase substantially the sensitivity of detection of influenza A virus by carrying out a polymerase chain reaction (PCR), using oligonucleotide sequences (amplimers) from the relatively conserved region of the viral hemagglutinin gene, preceded by reverse transcription (RT). The reverse transcription and the PCR are insensitive to single mutations by base exchange in this case, as long as the 3' end of the amplimer is not affected.

Abstract: A test kit useful for the determination of an immunological ligand includes a labeled receptor for that ligand, a specific wash solution and a test device. The wash solution is buffered to a pH of from about 5 to about 9 and contains at least 0.01 weight percent of a compound having a dodecyl sulfate anion and an alkali metal or ammonium cation. One such compound is sodium dodecyl sulfate. The test device has several test wells, and in each well there is a microporous membrane. A receptor for the ligand of interest is immobilized in one test well. The kit is particularly useful for measuring human chorionic gonadotropin as an early indicator of pregnancy.

Abstract: A diagnostic element for detecting the presence of anti-dsDNA antibodies in a sample. The diagnostic element includes a support (e.g., a microcell), a coating of mBSA on the support, dsDNA antigens immobilized on the coating, and a blocking layer for blocking immobilization sites other than ones occupied by dsDNA antigens. A testing kit is also provided which includes a diagnostic element, a sample diluent, an antibody solution, and a label identifying solution.

Abstract: Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.

Abstract: Compounds and methods for detecting the incorporation of a hapten into a protein or macromolecules are disclosed. The compounds comprise haptens bound directly or indirectly to a chromophoric group and a macromolecules-reactive group, whereby incorporation of the hapten into a protein or other macromolecules may be detected. The disclosure includes a compound of the formula: ##STR1## wherein n.sub.1 is 1, 2, 3, 4, 5, 6 or 7;n.sub.2 is 0, 1, 2, 3, 4, 5, 6 or 7;R.sub.1 is either a carboxytetramethyl-rhodamyl, sulforhodamyl101, or dinitrophenylaminohexanoyl group; andR.sub.2 is --CO.sub.2 H, --NH.sub.

Abstract: Immunochemical assays for human amylase isoenzymes are disclosed. These assays utilize monoclonal antibodies which are produced from hybridoma cell lines and are specific for human salivary amylase and ovarian tumor amylase but not human pancreatic amylase. The assays involve reacting this monoclonal antibody with the unknown sample for the purpose of studying quantitatively and qualitatively the amylase isoenzymes present. The results from such assays are useful in the diagnosis of disease or ruling out disease. Antibody producing hybridoma cell lines and their production are described.

Abstract: A buffered aqueous composition is useful simultaneously as a wash solution and a dye-providing composition in specific binding assays involving enzyme-labeled specific binding reagents. The wash composition includes a dye-providing composition, a buffer and an organic solvent having a certain molecular weight and water-solubility. Another useful composition includes a particulate substrate having avidin attached thereto, and a peroxidase reducing agent. Either composition can be provided in a diagnostic test kit, and can be used to detect a specific binding ligand in assays.

Abstract: Substantially pure modified .beta..sub.2 -microglobulin (m.beta..sub.2 m) of the formula I ##STR1## wherein R.sub.1 is 24-amino acid residue, with the sequence Ile-Gln-Arg-Thr-Pro-Lys-Ile-Gln-Val-Tyr-Ser-Arg-His-Pro-Ala-Glu-Asn-Gly-Ly s-Ser-Asn-Phe-Leu-Asn, R.sub.2 is a 30-amino acid residue with the sequence Tyr-Val-Ser-Gly-Phe-His-Pro-Ser-Asp-Ile-Glu-Val-Asp-Leu-Leu-Lys-Asn-Gly-Gl u-Arg-Ile-Gly-Lys-Val-Glu-His-Ser-Asp-Leu-Ser, R.sub.3 is a 20-amino acid residue with the sequence Trp-Ser-Phe-Tyr-Leu-Leu-Tyr-Tyr-Glu-Phe-Thr-Pro-Thr-Glu-Lys-Asp-Glu-Tyr-Al a, R.sub.4 is a 19-amino acid residue with the sequence Arg-Val-Asn-His-Val-Thr-Leu-Ser-Gln-Pro-Lys-Ile-Val-Lys-Trp-Asp-Arg-Asp-Me t, X is Phe, Phe-Ser, or Phe-Ser-Lys, and Y is Asp, Lys-Asp, or Ser-Lys-Asp is disclosed. The presence of the protein in body fluids is a diagnostic and/or prognostic marker for the development of a variety of disorders such as different types of cancer and diseases involving the immune system. Also disclosed are specific anti-m.

Abstract: Immunodiagnostic assays for the detection and determination of mastitis and sub-chemical mastitis comprise capturing neutrophils or fragments or soluble products thereof in a milk sample on an insolubilized form of a corresponding antibody, optionally using conditions whereby the cells in the milk sample are lysed. Monoclonal antibodies are provided which can be used in said assays and which are specific to neutrophils.

Abstract: Methods are disclosed for conducting assays. One such method comprises providing in combination a first bibulous member zone ("first zone") and a liquid medium containing a component. The first zone has non-diffusively bound thereto a reagent interreactive with the component. Conditions are selected wherein the liquid medium and at least a portion of the component contained therein traverse all of the first zone and migrate by capillary migration into a second bibulous member zone ("second zone"). The second zone is of a different composition than the first zone and is incapable of specifically binding the component except when an analyte is to be detected and the method further includes causing a reagent to become bound to the first bibulous member zone in relation to the amount of analyte present.

Abstract: The present invention provides a test carrier for the analysis of a sample liquid with a test layer which contains a ligand fixed to to carrier particles, which ligand reacts with a component of the sample liquid, the test layer having a three-dimensional open structure which is so porous that the sample liquid with the component can penetrate into it, the carrier particles being arranged in the layer in such a manner that the ligand, upon pentration of the sample liquid, comes into contact with the component of the sample, wherein the carrier particles consist of an inorganic material, on the surface of which reactive organic groups are covalently bound as coupling groups, and the ligand is covalently bound to the coupling groups. The present invention also provides processes for the production of such a test carrier and a method for using it.

Abstract: A process for preparing solid perfluorocarbon polymer supports permitting uniform and secure attachment of perfluorocarbon-substituted ligands or binders to carriers is provided utilizing pretreatment of the carriers with water miscible organic solvents.

Abstract: Immunoreagents for the release, non-specific capture and detection of lipopolysaccharides (LPS) that may be diagnostic for microorganisms causative for, among other things, Chlamydia trachomatis or Chlamydia psittaci are described.

Abstract: Certain phenalenimine fluorescent compounds represented by the structure ##STR1## wherein R' and R" are independently hydrogen, alkyl, cycloalkyl, aryl or a heterocycle, or R' comprises the carbon and heteroatoms which form a fused ring with the compound nucleus, are useful in biomedical and analytical determinations. These compounds can be used for staining cells, as well as for the determination of various analytes found in human or animal biological fluids. Such determinations can be carried out in solution or by using dry analytical elements. The fluorescent compounds can be reacted with quinone nuclei to form reducible compounds which are also useful in analytical methods. In addition, the compounds can be incorporated into what are known as "loadable" latex particles to form detectable labels and biological reagents.

Abstract: The invention relates to a novel assay for the determination of entities having biological activity and to a device for carrying out such determinations. The assay is a very sensitive one and quantities in the picogram per milliliter range can be determined. The assay is based on chrono-coulometric measurements with sequential measurements of a plurality of samples being carried out with the aid of a multiplexer, in combination with a potentiostat, there being provided suitable electrodes and means for applying a predetermined voltage. One of the electrodes is advantageously a glassy carbon electrode, carbon felt or cloth or carbon paper. Amongst biologically active entities there are antibodies/antigens; hormones/receptors; nuclotides/nucleotide probes, one of the members of such a pair being immobilized on an electrode surface, being tagged with an enzyme providing a signal in coulometric measurements.

Abstract: The invention refers to a method as well as a composition for the quantitative determination of kidney damages by the application of polyclonal and monoclonal antibodies against villin and/or fimbrin appearing in the urine as soon as damages of the kidney, for example reactions of rejection in case of a transplanted kidney or tubular inflammations, are occurring.

Abstract: An immunoassay method comprising applying an aqueous solution containing the analyte antigen to one end of a multi-zoned test strip device such that the solution moves along the strip by capillary action. The zones are arranged so that the solution (a) first contacts and reconstitutes dry, diffusible labelled component comprising colloidal gold conjugated to an antibody specific for said analyte antigen and then (b) contacts and reconstitutes dry, diffusible biotinylated second antibody specific for said analyte antigen such that a diffusible, dispersed sandwich reaction product forms. The reaction product diffuses along the strip with the solution and into a zone containing capture component consisting of a latex and avidin complex which avidin collects the reaction product by means of reaction with its biotin moiety. Thus, gold particles are collected and concentrated in the detection zone for visual determination.

Abstract: This invention relates to an improved assay device and assay for detecting or quantitating the presence or absence of a substance in a sample. The device has multiple layers comprising a permeable layer (a) having a capture reagent attached to less than the entire membrane, a selectively permeable layer (b) which does not allow assay reagents to pass through (b) and an absorbent layer (c). Layer (b) is in communication with layers (a) and (c). Layer (b) has at least one hole extending therethrough and the hole or holes are directly below the capture reagent in layer (a). The area of the hole or the combined area of the holes is less than the area covered by the capture reagent. This invention also relates to a method of reducing background color development in an absorbent layer of an assay device.

Abstract: The present invention provides a process for the determination of a specifically bindable substance by incubation of a sample solution with at least three receptors R.sub.1, R.sub.2 and R.sub.3, of which R.sub.1 is specifically bindable with R.sub.2 and R.sub.3, as well as with the substance to be determined, R.sub.2 brings about the binding to a solid phase and R.sub.3 carries a labelling, separation of bound labelling from unbound labelling and measurement of the labelling in one of the two phases, wherein, as receptor R.sub.1, a receptor is used which has at least two binding positions which bind specifically with an epitope of the substance to be determined, as R.sub.2 a conjugate of a partner P.sub.1 of a specifically binding pair and of a substance S which corresponds to the substance to be determined or is a derivative thereof and has at least one epitope of the substance to be determined, the partner P.sub.1 thereby either being bound to a solid phase or being immobilized, and as R.sub.

Abstract: Fermentation of S. erythraea produces the novel avermectin, 28-hydroxy ivermectin aglycone.

Abstract: Venom immunotherapy is a highly effective treatment for bee sting sensitive individuals. Treated individuals and those naturally exposed to repeated bee stings, such as beekeepers have been shown to develop anti bee venom anti-idiotypic antibodies. These antibodies can be isolated, monoclonal anti-bee venom antibodies can be generated and used in a diagnostic kit to evaluate whether or not an affected individual has developed effective immunity and to evaluate an individual's risk of sensitivity.

Abstract: A flow cytometry method for reproducibly detecting and counting a lymphocyte population of interest in a leukocyte suspension or whole blood sample in which the red cells are subsequently lysed. The suspension (or sample) is combined with a reagent comprising a primary antibody, either native, carrying an attached enzyme or biotin or other label, and a fixative reagent, in either order. Where the enzyme is not attached, an enzyme is coupled specifically to the primary antibody. The fixed suspension is reacted with a color-producing enzyme-cytochemical reagent. The suspension, now including stained and unstained fixed cells, is passed through a flow cytometer and the cells are characterized and counted on the basis of their light-scattering and light-absorbing properties.

Abstract: There are disclosed new compounds with significant antiparasitic activity which are prepared by fermenting 13-epi-ivermectin aglycone in a novel microorganism identified as Streptomyces avermitilis MA-5542. The 13-epi-ivermectin aglycone compounds are modified by the microorganism by methylation at the 5-hydroxy position and the addition of an .alpha.-L-oleandrose at the 13-position hydroxy. The compounds are significant antiparasitic and anthelmintic agents and compositions for that use are also disclosed.

Abstract: A carrier fleece is prepared for use as reagent carrier from which reagents can be dissolved in as assay such as immunological analysis. The carrier fleece contains from 5 to 60% by weight of cellulose-containing fibers, from 40 to 95% by weight of polyester or polyamide polymer fibers or a combination thereof and from 5 to 30% by weight of the fibers of an organic binding agent which has a hydroxyl or an ester group or a combination thereof. In an immunological analysis, the carrier fleece is impregnated with an immunologically active agent such as a beta-galactosidase conjugate and then introduced into a solution of a sample containing an immunologically active substance to be analyzed. The immunologically active agent is eluted into the sample solution and the presence of the immunologically active substance in the sample is determined.

Abstract: The present invention involves approaches to the detection of insect contamination of foodstuffs such as grain, for example. These approaches involve the detection of biological substances characteristic of insects. One such approach is an assay for the insect exoskeleton material, chitin. This test is particularly suited to the detection of live or dead specimens of the adult or egg stages of insects and for insect parts. Another type of assay uses an immunological approach to the detection and quantitation of an insect-specific protein such as the insect muscle protein, myosin or components thereof, for example. This type of test is well suited for detecting all stages of insect development from egg to adult, whether live or dead. It should also provide an assay system that correlates well to the current insect fragment assay.

Abstract: Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.

Abstract: The present invention relates to dual analyte enzyme immunoassays for assaying two antigens in a single liquid sample wherein the two immunoreactions are carried out simultaneously and wherein subsequently the two enzyme reactions occur simultaneously. Suitable enzyme/substrate pairs are beta-galactosidase/nitrophenyl-beta-D-galactoside (p- an/or o-) and alkaline phosphatase/phenolphthalein monophosphate.

Abstract: Antibacterial and antitumor agents designated LL-E33288 complex and their production by new strains of Micromonospora echinospora spp. calichensis NRRL-15839, NRRL-15975 and NRRL-18149, are disclosed.

Abstract: An assay employing a tracer comprising a ligand having a mercury label wherein mercury label is released from at least one of a bound or free tracer phase and interacts with a metal. Analyte is determined by a change in at least one property of the metal caused by such interaction. The invention also relates to a device for such an assay wherein mercury ions released from a free or bound tracer are caused to eventually amalgamate with a metal, and the presence and/or amount of analyte is determined by changes in the metal resulting from the eventual amalgamation which may be measured electrically or by other means. The invention also relates to novel assay instruments, novel lancets, assay sensors, assay sensor packets, instrumentation and combinations of assay components, and related methods.

Abstract: Two new antibiotics which are now nominated as benanomicin A and benanomicin B, respectively, are fermentatively produced by the cultivation of a new microorganism, designated as MH193-16F4 strain, of Actinomycetes. Benanomicins A and B each show antifungal activity and are useful as a therapeutic antifungal agent. A new compound, dexylosylbenanomicin B is now produced by chemical conversion of benanomicin B, and this semi-synthetic antibiotic also shows antifungal activity and is useful as a therapeutic antifungal agent.

Abstract: Methods are described for making specific monoclonal antibodies which may be used in a sensitive immunoassay for detection of synthetic pyrethroids in foods and environmental samples. Appropriate sample preparation and enzyme amplification of the immunoassay for this widely-used class of pesticides permits detection at low levels in laboratory and field tested samples.

Abstract: An antifungal compound, demethylallosamidin, represented by the formula: ##STR1## is disclosed. Methods of production and antifungal compositions comprising demethylallosamidin are also provided.

Abstract: Disclosed herein are antibiotic BU-3608 D and E isolated from Actinomadura hibisca. These compounds are active antifungal agents.

Abstract: Modified nucleotides are provided which have the structure ##STR1## wherein R.sup.1 is a reactive group derivatizable with a detectable label, R.sup.2 is an optional linking moiety including an amide, thioether or disulfide linkage or a combination thereof, R.sup.3 is hydrogen, methyl, bromine, fluorine or iodine, R.sup.4 is hydrogen, an acid-sensitive, base-stable blocking group of an acyl capping group, R.sup.5 is hydrogen or a phosphorus derivative, R.sup.6 is H, OH, or OR where R is a protecting group and x is an integer in the range of 1 and 8 inclusive. Methods of synthesizing the derivatizable nucleotide are disclosed, as are labeled polynucleotide probes prepared therefrom.

Abstract: This invention is directed to a ligand-receptor assay for determining the presence or amount of at least one target ligand, capable of competing with a ligand analogue conjugate for binding sites available on a ligand receptor, said ligand analogue conjugate comprising at least one ligand analogue coupled to a signal development element capable of emitting a detectable signal, in a fluid sample suspected of containing said target ligand, comprising the steps of:a. contacting said fluid sample with ligand analogue conjugate and ligand receptor to form a reaction mixture, the relative amounts of ligand analogue conjugate and ligand receptor being such that in the absence of target ligand, and subsequent to substantially equilibrium binding, substantially all of the ligand analogue conjugate is bound to ligand receptor;b. detecting the unbound ligand analogue conjugate;c. relating the detectable signal to the presence or amount of target ligand in the fluid sample.

Abstract: The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide hormone analogues is exemplified by human humoral hypercalcemic factor (hHCF), wherein Lys.sup.13 is modified so as to produce HCF analogues which can inhibit the action of HCF.

Abstract: The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide hormone analogues is exemplified by human humoral hypercalcemic factor (hHCF), wherein Lys.sup.13 or Lys.sup.11 is modified on the epsilon-amino group by biotin so as to produce HCF analogues which can inhibit the action of HCF.